AllSight
Companies · VCYT · Services-Medical Laboratories

VERACYTE, INC. (VCYT)

VERACYTE, INC. (VCYT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

VERACYTE, INC. (VCYT) stock — financials & valuation

Key numbers for VERACYTE, INC. (VCYT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 65/100 — a percentile rank of VERACYTE, INC.’s fundamentals against Services peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$3.7B
P / E32.3×
P / S6.6×
EV / EBITDA26.9×
Gross margin71.7%
Operating margin18.8%
Net margin20.4%
Return on equity8.2%
ROIC9.6%
Revenue growth17.3%
Debt / equity0.0×
Dividend yield0.0%

Is VERACYTE, INC. overvalued? P/S looks fair vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from VERACYTE, INC.’s own financial statements and shown as context, never as advice.

Sep 14, 2026$150M acquisition
Veracyte buys Convergent for $150M, adding a 2028 bladder-cancer test
Related companies in Services-Medical Laboratories
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact